Non-virulent Porphyromonas gingivalis mutant

Abstract

A non-virulent, recA defective mutant of Porphyromonas gingivalis. A pharmaceutical composition comprising the Porphyromonas gingivalis strain of the present invention.

I claim:  
     
         1 . A non-virulent, recA defective mutant of Porphyromonas gingivalis.  
     
     
         2 . A pharmaceutical preparation comprising the mutant of Porphyromonas gingivalis according to  claim 1 .  
     
     
         3 . A method of decreasing the growth rate or reproduction rate of wild-type Porphyromonas gingivalis in a mammal, the method comprising administering to the mammal at least one dose of the mutant of Porphyromonas gingivalis according to  claim 1 .  
     
     
         4 . The method of  claim 3 , wherein the mammal is a human.  
     
     
         5 . The method of  claim 3 , wherein the administration comprises injecting the mammal with the at least one dose of the non-virulent, recA defective mutant of Porphyromonas gingivalis via a route selected from the group consisting of a subcutaneous route, an intravenous route and an intramuscular route.  
     
     
         6 . The method of  claim 3 , wherein the dose administered is between about 1×10 3  and 1×10 7  the mutant of Porphyromonas gingivalis per kg of body weight of the mammal.  
     
     
         7 . A method of decreasing the growth rate or reproduction rate of Porphyromonas gingivalis in a mammal, the method comprising the step of administering to the mammal at least one dose of a non-virulent, recA defective mutant of Porphyromonas gingivalis.  
     
     
         8 . The method of  claim 7 , wherein the mammal is a human accession number 202109 to the mammal.  
     
     
         9 . The method of  claim 7 , wherein the step of administering comprises injecting the mammal with the at least one dose of a non-virulent, recA defective mutant of Porphyromonas gingivalis via a route selected from the group consisting of a subcutaneous route, an intravenous route and an intramuscular route.  
     
     
         10 . The method of  claim 7 , wherein the step of administering comprises injecting the [mutant] mammal with the at least one dose of a non-virulent, recA defective mutant of Porphyromonas gingivalis, wherein the dose is between about a 1×10 3  and 1×10 7  bacteria per kg of body weight.